Floatz logo

Rituximab

Primary Effusion Lymphoma

Explore 19 assets in Primary Effusion Lymphoma →
Floatz Rating
BB70/100
Confidence
Indicative
v0.2
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07649304CT.gov
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
—Not Yet Recruiting———
NCT03220022CT.gov
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
—Active Not Recruiting———
NCT02337985CT.gov
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
—Active Not Recruiting———
NCT02228512CT.gov
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
—Withdrawn———
NCT01193842CT.gov
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
—Completed———
NCT00310128CT.gov
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
—Withdrawn———
NCT00183976CT.gov
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Primary Effusion Lymphoma

AssetSponsorPhaseRating
Rituximab (this asset)National Cancer Institute (NCI)P2BB · 70
Vincristine SulfateNational Cancer Institute (NCI)P2BBB
EtoposideNational Cancer Institute (NCI)P2BBB
CyclophosphamideNational Cancer Institute (NCI)P2BB
PrednisoneNational Cancer Institute (NCI)P2BB
AdriamycinNational Cancer Institute (NCI)P2BB
(+)-VincristineNational Cancer Institute (NCI)P2BB
ProcarbazineAIDS Malignancy ConsortiumP2BB
NivestimCity of Hope Medical CenterP2B

+30 more in the Primary Effusion Lymphoma cohort

Other indications for Rituximab

IndicationSponsorPhaseRating
Lymphoblastic Lymphoma—P4BBB · 75
Grade III Lymphomatoid Granulomatosis—P2BBB · 74
Testicular Lymphoma—P2BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Rituximab in Primary Effusion Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 13, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-primary-effusion-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →